|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
06833 SINCO PHARMA
Nominal 
0.145 0.000 (0.000%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 1,032,475 | -13.659% | 2,084,573 | 2,821,321 | 2,540,063 | 2,271,505 |
| Cost of Sales | (908,386) | -14.715% | (1,862,483) | (2,521,380) | (2,216,783) | (1,965,637) |
| Gross Profit | 124,089 | -5.057% | 222,090 | 299,941 | 323,280 | 305,868 |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | -- | -- | -- | (4,922) | (3,000) | (2,354) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 0 | -- | 0 | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 30,141 | -17.548% | 48,259 | 98,920 | 99,881 | 99,292 | |
| Taxation | (10,232) | -15.904% | (13,407) | (56,875) | (57,529) | (29,830) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | 0 | -- | 0 | 0 | 0 | 0 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 19,909 | -18.369% | 34,852 | 42,045 | 42,352 | 69,462 | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 12,609 | -26.229% | 29,915 | 10,529 | 8,467 | 15,911 |
| Depreciation & Amortisation | 16,221 | 10.324% | 25,581 | 24,495 | 16,319 | 11,356 |
| Directors' Emoluments | -- | -- | 9,732 | 10,729 | 9,384 | 4,872 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 0.980 | -18.333% | 1.700 | 2.100 | 2.000 | 3.400 |
| DPS (cts) | 0.000 | -- | 0.147 | 0.185 | 0.354 | 0.858 |
| Dividend Payout Ratio (%) | -- | -- | 8.632% | 8.829% | 17.682% | 25.231% |
| Cash flow per share ($) | -- | -- | 0.102 | (0.115) | 0.174 | 0.037 |
| NBV per share ($) | 0.350 | -- | 0.341 | 0.326 | 0.309 | 0.297 |
| Remarks: | Real time quote last updated: 11/09/2026 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 19,909 |
| %Change | -18.369% |
| EPS / (LPS) | RMB 0.010 |
| NBV Per Share (¥) | RMB 0.350 |